# 1. Financial Performance ## A. Key Figures * **Total Revenue:** **₹6,813 Cr** FY26 (+23%) · **₹1,812 Cr** Q4 (+5%) * **PAT:** **₹889 Cr** FY26 (+148%) · **₹279 Cr** Q4 * **EBITDA Margin:** **26.8%** FY26 (+670 bps) · **28.9%** Q4 * **Gross Margin:** **60.4%** FY26 (+540 bps) · **61.4%** Q4 * **Leverage & Returns:** **1.25x** Net Debt/EBITDA (vs 2.3x YoY) · **17.7%** ROCE (vs 9.7% YoY) ## B. Revenue & Profitability Drivers * **Segment Momentum:** Robust annual top-line expansion fueled by the **CDMO business** and the **Affordable Medicine (Generics)** portfolio. * **Operating Leverage:** Significant bottom-line outperformance and margin expansion driven by a favorable product mix and aggressive process improvement efforts. * **Resilience:** Quarterly income maintained a growth trajectory despite prevailing macroeconomic challenges and geopolitical pressures. ## C. Margin & Tax Outlook * **Efficiency Gains:** Management is utilizing increased capacity and operational mix optimization to hedge against rising input costs. * **Tax Guidance:** The effective tax rate is projected to stabilize between **25% and 26%** for the upcoming period. ## D. Capital Structure & Liquidity * **Deleveraging Profile:** Substantial improvement in debt-to-EBITDA ratio supported by strong internal cash flows, despite a net debt position of **INR 2,285 crores**. * **Forward Leverage:** While absolute gross debt may rise slightly in FY27, the leverage ratio is expected to remain stable or soften. * **Capital Efficiency:** Sharp recovery in ROCE metrics reflects improved asset utilization and higher earnings quality compared to the previous fiscal. --- # 2. CDMO & Small Molecules ## A. Key Figures * **CDMO Annual Revenue:** **₹2,080 Cr** Total · **>1/3** of Total Revenue * **Small Molecule Revenue:** **₹1,896 Cr** (+38%) * **Revenue Mix Shift (6-Year):** **>30%** CDMO (from 13%) · **41%** ARV (from 67%) * **Project Transitions:** **3** Projects moved from development to commercial phase ## B. Segment Performance * **Robust Growth Drivers:** Accelerated performance in the small molecule space is underpinned by late-stage pipeline programs and the supply of complex NCE compounds. * **Strategic Scale:** Management highlights that the current CDMO scale is significant relative to peers, with a clear distinction between proprietary CDMO services and fully integrated generic CMO projects. * **Ancillary Verticals:** Animal Health contributed meaningful shipments with strong FY27 expectations, while Crop Science remains in a multi-year gestation period for significant ramp-up. ## C. Pipeline Commercialization * **High Commercial Visibility:** Management reports low uncertainty for products that have cleared commercialization gates at the Bangalore facility, aligning with partner volume projections. * **Strategic Partnerships:** The company operates as a strategic partner for major pharma, maintaining a robust RFP pipeline across all clinical stages. * **Sector Diversification:** Electronics sector initiatives remain in early development with demand outlook expected to clarify in **a few more quarters**. ## D. Technology Platforms * **Advanced Manufacturing Focus:** Significant investments are directed toward high-value platforms at Vizag, including **biocatalysis, flow chemistry, and high potent APIs**. * **Success Metrics:** Management prioritizes reactor capacity and R&D capabilities over program counts, noting individual program values can reach **$50 million**. * **AI Resilience:** Disruption risk from AI is viewed as minimal as the company focuses on manufacturing rather than discovery; however, AI-driven molecule design is increasing the demand for complex synthesis. ## E. Long-term Mix * **Strategic Rebalancing:** The long-term roadmap targets a **50%** revenue contribution from the CDMO segment by **2030**, continuing the shift away from ARV concentration. * **Value Chain Positioning:** Focus remains on high-value APIs and advanced intermediates to ensure sustainability and superior customer offerings over basic intermediates. --- # 3. Manufacturing & Infrastructure ## A. Key Figures * **Total Reactor Volume:** **>8,200 cubic meters** Small Molecule/API/Intermediate capacity * **Annual Capex:** **₹1,070 Cr** Total FY investment · **₹335 Cr** Q4 investment * **Laurus Bio Sales:** **₹65 Cr** Q4 (+124%) · **15%** Full-year growth * **Fermentation Capacity:** **250,000 liters** Current · **400,000 liters** Additional by year-end * **Asset Turnover:** **0.89** Ratio following 20% CDMO growth ## B. Capacity Expansion * **Strategic Capex Allocation:** Management is prioritizing mid-to-large scale infrastructure, with **90% of project spend** and **75% of total investment** dedicated to scaling CDMO and CMO capabilities. * **Order-Book Driven Growth:** Expansions are non-speculative and backed by existing contracts, including a **300 crore tablet contract** facility now largely online and ready for Q1 revenue generation. * **De-risking Commercial Launches:** Investing in large-scale capacities ahead of launch allows for validation and engineering batches at final scale, eliminating typical scale-up uncertainties for Big Pharma partners. * **Future Scale-Up:** Plans include four additional units by **FY28** to add significant reactor volume, alongside a transition to larger **110,000-liter fermenters** as products reach full commercial maturity. ## C. Fermentation & Bio * **Segment Scaling:** Since the 2021 Richcore acquisition, segment revenues have surged to **₹185–190 Cr** with EBITDA reaching **₹35–40 Cr**. * **Portfolio Diversification:** Expansion at the Vizag site (Unit 4) is pivoting toward high-titer non-pharmaceutical products, including industrial chemicals, surfactants, and polymers. * **Infrastructure Roadmap:** A new greenfield fermentation site (Phase 1) and a **400 KL** capacity expansion in Vizag are on track to be operational by the **end of 2026**. ## D. Asset Utilization & Project Timelines * **Operational Efficiency:** Recent commercializations utilized identical equipment trains for validation and production, resulting in zero yield or quality challenges during the pilot-to-commercial transition. * **Near-Term Milestones:** Key upcoming triggers include peptide validation in **Q2 FY27**, Unit 7 commercial validation by **March 2027**, and the KRKA JV facility completion by **mid-2027**. * **Downstream Advantage:** New product manufacturing faces minimal risk due to the absence of tedious processing requirements and low contamination profiles. --- # 4. Affordable Medicines & Generics ## A. Key Figures * **Division Revenue:** **₹1,223 Cr** Q4 · **₹4,733 Cr** FY26 (+18%) * ARV Business Revenue: ₹2,800 Cr FY26 (Exceeded guidance of ₹2,500 Cr +/- ₹200 Cr) * **ARV Revenue Mix:** **~66%** API sales · **~33%** Finished Formulations * Formulation Capacity: 12 billion units (+20% YoY) * **Regulatory Pipeline:** **92** Cumulative DMF filings · **94** Cumulative product filings ## B. ARV Portfolio * **Market Leadership:** Company maintains a dominant global position, providing treatment for **one-third** of the global HIV population. * **Operational Efficiency:** Full-year outperformance driven by maximum asset utilization; gross margin expansion achieved through raw material softening and process improvements despite flat pricing. * **Strategic Pivot:** While absolute ARV revenue is projected to stabilize at approximately **₹2,500 Cr (+/- ₹300 Cr)**, its relative contribution to the total mix will decline as the company diversifies. ## C. Non-ARV Growth & Formulation Strategy * **Diversification Momentum:** Robust annual growth in the Affordable Medicines segment was fueled by volume gains in non-ARV portfolios, specifically oncology. * **Sustained Outlook:** Management expects the growth momentum in non-ARV formulations observed in FY26 to carry forward into FY27. * **Capacity Optimization:** Future scaling relies on a **20% increase** in oral solid facility capacity and the ramp-up of new product launches across developed and emerging markets. --- # 5. R&D & New Modalities ## A. Key Figures * **R&D Spend:** **4.1%** of sales (+10% YoY) * **Regulatory Compliance:** **132** Quality Audits passed (Zero critical findings) ## B. Peptide Capabilities * **Infrastructure Readiness:** Commercial-scale peptide manufacturing block is nearing completion to support large-scale capacity requirements. * **Market Positioning:** Active engagement in the high-growth weight loss sector with multiple medium-term opportunities in the collaborative pipeline. * **Strategic Discretion:** Management is withholding specific tonnage and capex data for peptide initiatives despite significant ongoing investments. ## C. Cell & Gene & Advanced Modalities * **Biotech Diversification:** Aggressive expansion into advanced therapies, including gene therapy and ADC manufacturing in Hyderabad and CAR-T cell therapy in Mumbai. * **Technological Breadth:** R&D focus has widened to include cell culture, precision fermentation, enzymes, and biocatalysis to future-proof the biotech portfolio. * **Investment Continuity:** R&D intensity expected to remain stable at current levels relative to sales to fund ongoing modality shifts. ## D. Regulatory Compliance * **Operational Excellence:** Maintained a clean regulatory track record across a high volume of audits while advancing integrated EHS/ESG compliance systems. --- # 6. Risks & Geopolitical Factors ## A. Supply Chain & Operational Resilience * **Logistics Stability:** Management maintained consistent supply despite global headwinds, though **geopolitical disruptions** remain a monitored risk for near-term On-Time In-Full (OTIF) performance. * **Operational Continuity:** Production remains unaffected by recent input cost spikes, with sufficient visibility to maintain full operations through the **end of June**. ## B. Portfolio & Concentration Risk * **Diversification Strategy:** The CDMO business is increasingly de-risked through a broad program base, reducing reliance on any single clinical or commercial asset for revenue visibility. * **Inventory & Patent Health:** Commercialization of new APIs with long patent lives has mitigated destocking concerns and concentration risks based on current partner forecasts. ## C. Clinical & Market Outlook * **Commercialization Timelines:** While late-stage molecule launches for **FY '27** face inherent clinical uncertainty, the overall segment maintains a positive long-term growth trajectory. * **Input Cost Management:** Operations proved resilient against a **solvent price increase** in **Q4 FY '26**, with no curtailment of production required. --- # 7. Guidance & Outlook ## A. Key Figures * **EBITDA Margin:** ~29% Q4 FY '26 exit rate * **Cumulative Capex:** **₹3,000 Cr** over FY '27 and FY '28 * **Annual Capex:** **₹1,500 Cr** per annum (revised up from ₹1,000 Cr) ## B. Revenue Trajectory * **CDMO Momentum:** Management anticipates robust year-on-year expansion for the CDMO segment in FY '27, underpinned by a well-established order book. * **New Growth Levers:** Revenue visibility for the **LORDIN OLED collaboration** is expected within two quarters; details on the **500-acre Atchutapuram greenfield project** are also slated for next quarter. ## C. Margin Sustainability * **Profitability Floor:** Management expresses confidence in maintaining or improving the recent peak EBITDA margins through FY '27, citing favorable product mix and operating leverage. * **Operating Leverage:** While gross margins are expected to remain stable across project phases despite **solvent pricing volatility**, EBITDA margins are projected to scale during commercialization due to higher volumes. ## D. Capex Roadmap * **Capacity Expansion:** Significant upward revision in capital outlay to support specific product visibility and customer demand over the next two years. * **Strategic Focus:** Investment is primarily categorized as growth capex, backed by clear production volume requirements rather than speculative building.